Skip to content

Advances in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital.

Featured In Neuroscience

Shibani S. Mukerji, MD, PhD, of the Neuro-Infectious Diseases Unit at Massachusetts General Hospital, discusses the neuropathological features of COVID-19. In this video, She details the impact the virus has on the brain, showing that there is minimal viral presence.

Featured In Orthopaedics

In this video, Brian E. Grottkau, MD, chief of the Pediatric Orthopaedic Service and director of the Lab for Therapeutic 3D Bioprinting at Massachusetts General Hospital, discusses some of the research projects currently underway at the lab.

Featured In Cardiovascular

Massachusetts General Hospital specialists collaborate to identify problems earlier in people with diabetes and peripheral artery disease, improving chances of limb preservation.

Featured In Research and Innovation

Jehan W. Alladina, MD, and Benjamin D. Medoff, MD, of the Division of Pulmonary and Critical Care Medicine, and colleagues advise that high plasma concentrations of soluble suppression of tumorigenicity-2 may signify persistent lung injury in COVID-19 respiratory failure and the need for continued ventilatory support.

Featured In Orthopaedics

Christian Klemt, PhD, Anand Padmanabha, MD, Young-Min Kwon, MD, PhD, and colleagues have determined that utilization of revision total hip and knee joint arthroplasty (TJA) in racial/ethnic minorities is worse than for primary TJA, and a number of post-revision outcomes are significantly worse than for white patients.

The Latest Digestive Health Advances

Vishwajith Sridharan, MD, MBA, and Yasmin G. Hernandez-Barco, MD, of the Division of Gastroenterology, confirm the aggressive nature of pancreatic acinar cell carcinoma but report that surgical resection in localized disease had a significant survival benefit.

Richard A. Hodin, MD, discusses the advances his team at the Crohn's and Colitis Center at Massachusetts General Hospital has made in treatment for patients with irritable bowel disease.

Contributing Physicians

Surgical Director of the Liver Program, Division of General Surgery, Associate Professor of Surgery, Harvard Medical School

Gapontsev Family Endowed Chair in Surgical Oncology, Massachusetts General Hospital

Motaz Qadan, MD, PhD photo

Advances Specialties

Cardiovascular

Cardiologists at Massachusetts General Hospital have gathered real-world data on adverse events related to the implantation of the original Watchman left atrial appendage closure device, including events that occurred a year or more after the implant procedure.

Oncology

Vishwajith Sridharan, MD, MBA, and Yasmin G. Hernandez-Barco, MD, of the Division of Gastroenterology, confirm the aggressive nature of pancreatic acinar cell carcinoma but report that surgical resection in localized disease had a significant survival benefit.

Orthopaedics

Most orthopedic surgeons who responded to a survey at Massachusetts General Hospital said they expect risk prediction models powered by artificial intelligence to be integrated into their practices before the decade is out.

Education & Training Opportunities

October 16-20, 2021

The 2021 CNS Annual Meeting is organized by Congress of Neurological Surgeons (CNS) and will be held from October 16-20, 2021, in Austin, Texas. Experts from the Massachusetts General Hospital Department of Neurosurgery will present on leading research and innovative treatment approaches.

November 5-6, 2021

The Mass General Short-term Heart/Lung Support Symposium is designed to provide the opportunity to learn, ask questions, participate in simulation exercises and review the rare but potentially fatal problems that can occur with all forms of mechanical assist in a low stress environment for all team members.

Clinical Trials

In Neuroscience

The study involves multiple visits over 6 months. You will complete an 8-week stress reduction treatment that includes a medical device worn in the ear and attend MRI and PET scans. You will also complete daily migraine diaries online.

In Neuroscience

We are looking for adults 55-80 years old with Alzheimer's Disease to receive infusions of an experimental drug, JNJ-63733657, or a placebo (inactive) infusion. This study will help us determine the safety and efficacy of JNJ-63733657.